Christian S. Schade
President and Chief Executive Officer
Mr. Schade has more than 30 years of private and public pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in the investment banking industry. Prior to joining Aprea Therapeutics, he was Chief Executive Officer of Novira Therapeutics, which was acquired in December 2015 by Johnson & Johnson in an all-cash transaction. Prior to joining Novira, Mr. Schade was Executive Vice President and Chief Financial Officer at Omthera, a NASDAQ-listed specialty pharmaceuticals company focused on the development and commercialization of new therapies for dyslipidemia. At Omthera, Mr. Schade was responsible for all corporate finance, accounting and business development activities, and led the sale of Omthera in July 2013 to AstraZeneca. He also was Executive Vice President and Chief Financial Officer at NYSE-listed NRG Energy, and from 2000 to 2009, he was Senior Vice President of Administration and Chief Financial Officer at Medarex, a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders and infectious diseases. Mr. Schade played a pivotal role in the acquisition of Medarex by Bristol-Myers Squibb, leading the negotiations for the sale and the eventual merger-integration process of the research, development and administrative functions. Before joining Medarex, Mr. Schade served as Managing Director at Merrill Lynch in London and held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade received an MBA from the Wharton School at the University of Pennsylvania and an AB from Princeton University. Mr. Schade currently serves on the Board of Directors of Integra Life Sciences Inc. and the Board of Directors of Indivior PLC.
Lars Abrahmsen, PhD
Senior Vice President and Chief Scientific Officer
Dr. Abrahmsen has more than 25 years of experience in research and drug development in the pharmaceutical industry, both with small molecules and biopharmaceuticals. Beginning with postdoctoral work at Genentech, he has also worked at Biovitrum, Pharmacia&Upjohn, Pharmacia and KabiGen. More recently he served as Chief Scientific Officer at Affibody from 2004-2010 and as SVP of Protein Therapeutics at Algeta from 2010-2013. Dr. Abrahmsen has experience from discovery research to preclinical development and has primarily focused on projects within oncology and metabolic diseases. Dr. Abrahmsen received a PhD in Biochemistry and an MS in Chemistry, both from the Royal Institute of Technology in Stockholm, Sweden.
Gregory A. Korbel, PhD
Vice President of Business Development
Dr. Korbel has 10 years of experience in the biotechnology and pharmaceutical industries. Prior to joining Aprea Therapeutics, he was Director of Business Development and Operations at Novira Therapeutics, which was acquired in December 2015 by Johnson & Johnson, and served as Director of Research Operations subsequent to the acquisition. In addition to consulting for venture capital and biotechnology firms, he formerly served as Senior Scientist at Invtirogen/Life Technologies. Dr. Korbel received an MBA from the Wharton School at the University of Pennsylvania, a PhD in Chemistry from Harvard University and a BA from Vanderbilt University.
Mikael von Euler, MD, PhD, FFPM
Consultant and Medical Adviser
Dr. von Euler is a medical oncologist with more than 25 years of experience in the pharmaceutical industry and was formerly Chief Medical Officer at Aprea Therapeutics. He was also Chief Medical Officer at Oncos Therapeutics, where he continues to serve as a Medical Adviser. Dr. von Euler has also served as Cluster Head for the Her2 area (Herceptin, pertuzumab, T-DM1) at Roche/Genentech, Vice President of Oncology Europe at GlaxoSmithKline and Global Product Director of Arimidex/Nolvadex at AstraZeneca. Dr. von Euler received his MD and PhD degrees from the Karolinska Institute in Stockholm, Sweden.